Beam Therapeutics Price Target Maintained With a $27.00/Share by RBC Capital
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $27
RBC Capital analyst Luca Issi maintains $Beam Therapeutics(BEAM.US)$ with a hold rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 22.6% and
RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)
Jones Trading Initiates Coverage On Beam Therapeutics With Hold Rating
JonesTrading Initiates Beam Therapeutics(BEAM.US) With Hold Rating
JonesTrading analyst Soumit Roy initiates coverage on $Beam Therapeutics(BEAM.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 23.5% and a total average return
Hold Rating on Beam Therapeutics Amid Competitive Pressure and Absence of Clinical Data
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $69
Stifel analyst Dae Gon Ha maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and adjusts the target price from $66 to $69.According to TipRanks data, the analyst has a success rate of 46.0%
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $69
Stifel analyst Benjamin Burnett maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and adjusts the target price from $103 to $69.According to TipRanks data, the analyst has a success rate of 35
Beam Therapeutics Is Maintained at Buy by Stifel
Express News | Beam Therapeutics Inc : Stifel Raises Target Price to $69 From $66
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
H.C. Wainwright analyst Patrick Trucchio maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 3
Optimistic Outlook on Beam Therapeutics: Advancements and Potential in Precision Genetic Medicines
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine With CRISPR Technology
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Beam Therapeutics: Hold Rating With Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases
Beam Therapeutics Price Target Cut to $31.00/Share From $33.00 by Barclays
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target